Tackling the clinical challenges of GU Oncology

From advances in the screening of prostate cancer to the management of the genitourinary tumors, the GU oncology addresses ever more clinical challenges.  What are the most relevant challenges in the management of the prostate cancer population? "It is crucial to balance the right treatment strategy with the right endpoint for patients": Professor Silke Gillessen gets straight to the point of the question posed by Dr Giuseppe Procopio, Head of the Department of Genitourinary Medical Oncology Unit at IRCCS National Cancer Institute Milan, and Editor of the GU Section of the Tumori Journal. The guest expert of this TJ Talks podcast is Silke Gillessen, Medical and Scientific Director of the Oncology Institute of Southern Switzerland and Full Professor at University of Italian Switzerland, focusing her research in genitourinary areas. In terms of endpoints - she continues - overall survival is the gold endpoint. But when it comes to metastatic prostate cancer, it is necessary to aim for a mix of quality of life, which is very important, and oncological outcomes. These should include improvements related to patients' quality of life, such as time to progression and time to symptomatic events. Patients remind us that we must think not only about the disease, but also about their well-being. Learn more about the genitourinary cancer care scenario from one of the leading voices in the field. Enjoy your listening!See omnystudio.com/listener for privacy information.